We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Signaling Pathways of Cardiac Remodeling Related to Angiotensin II

Carolina Baraldi Araujo Restini,
Arthur F. Engracia Garcia, Henrique Melo Natalin,
Guilherme Melo Natalin and Elen Rizzi

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/66076>

Abstract

Heart failure affects more than 23 million people worldwide, and its prognosis remains poor. Hypertension is one of the most prominent human health problem and places individuals at a higher risk for heart failure. Several factors interplay the development of hypertension contributing for decompensated heart hypertrophy. The renin-angiotensin system (RAS) has been shown to be the foremost regulator of blood pressure. Many evidences have pointed out the importance of RAS and its key mediator, angiotensin II (Ang II), on signaling pathways involved in cardiac remodeling. The Ang II-induced hypertrophic effects seem to be related to increased reactive oxygen species (ROS). Under oxidative stress conditions, as those observed in hypertension and heart failure, the matrix metalloproteinases (MMP) is activated. Ang II is connected with TNF- α and TGF- β by ROS-NF- κ B-MMP mechanisms, which are involved in heart failure. The rationale of the present chapter is structured on the progression of heart failure related to Ang II, TNF- α and TGF- β by common signaling pathways. Pharmacotherapeutics approaches to the heart failure abound, but the mortality rates remain high. This chapter will also describe molecular mechanisms involved in heart failure highlighting that TGF- β and/or TNF- α inhibitors could contribute to treatment to this serious clinical condition.

Keywords: heart failure, renin-angiotensin system (RAS), hypertension, transforming growth factor-beta (TGF- β), tumor necrosis factor (TNF)- α , metalloproteinases (MMP)

1. Introduction

Cardiac remodeling is generally triggered due to cardiovascular diseases, such as myocardial infarction, pressure overload, idiopathic dilated cardiomyopathy or volume overload [1].

Cardiac remodeling is also the most common factor in heart failure progress, a chronic disease defined as a complex syndrome. In this sense, heart failure is associated with intensive and progressive cardiac structural and functional modifications, leading to impaired cardiac output [2, 3].

More than 23 million people worldwide are affected by heart failure. In the United States, approximately 5 million patients have heart failure and this number increases by more than half a million cases per year [4]. It is estimated that an increase in the 46% in the prevalence of heart failure from 2012 to 2030 in people with 18-year old or more [5].

There are several criteria to diagnose heart failure as revised by Roger VL [6]. These criteria are important to determine the kind of heart failure treatment and also contribute to improving the accuracy of epidemical data. Despite the progress of the heart failure treatment, mortality rates are still high. Nowadays, the available treatments for heart failure improve the survival rates but raise hospitalizations as well as hospital readmissions. Among these treatments, there are angiotensin-converting enzyme inhibitors (ACEi) and beta-adrenoceptors blockers that alleviate the symptoms in individuals with advanced heart failure and depressed ejection fraction in end-stage disease [7]. Therefore, heart failure is a growing public health problem, in which a projection from 2012 to 2030 heart failure will account more than \$69 billion in health-care cost in the United States. It will be a significant increase from 127% [5].

Several risk factors are associated with heart failure, such as smoking, obesity, diabetes mellitus, coronary heart disease and hypertension among others. Hypertension—chronic elevation of blood pressure—is the most prominent human health problem, and it is the main comorbidity linking obesity, cardiovascular and metabolic diseases. According to Framingham study, hypertension is considered the major risk factor attributed to heart failure, and its prevalence in hypertension exceeds 50% [6, 8]. Hereupon, hypertension is the cause of deaths because it often coexists with heart failure and also places individuals at a higher risk for kidney failure, stroke, etc.

2. The progression of cardiac remodeling in hypertension

Hypertension-induced cardiac remodeling is an initial adaptive response of the heart in order to compensate the increased left ventricle wall stress induced by an augmented hemodynamic load. This remodeling is named adaptive hypertrophy, which is featured by growing inwards of the left ventricle and septum wall, resulting in a reduction in left ventricle chamber (**Figure 1**) [2, 3]. The structural changes may occur due to additional contractile-protein units within the cardiomyocytes leading to an expansion in the myocyte width. In parallel to the cellular growth, the cardiac extracellular matrix is also hypertrophied. An important hallmark in

chronic hypertension is the intensive turnover from the extracellular matrix, resulting in a progressive collagen deposition [3]. Amount evidences have shown that the cardiac fibrosis could contribute to initial diastolic dysfunction harming the re-lengthening of myocytes during diastole [2, 8, 9]. Thus, despite being called “adaptive”, this hypertrophy generates several maladaptive molecular and/or cellular mechanisms triggered in the initial remodeling.

Figure 1. The hypertension induced progression from adaptive hypertrophy to maladaptive hypertrophy. Cardiac remodeling is progressive in hypertension. Initially, an adaptive hypertrophy occurs in the left ventricle that grows inwards reducing the left ventricle chamber. The cardiac remodeling may progress to maladaptive hypertrophy. The left ventricular chamber is dilated and left ventricle and septum wall are thinned. The strength of cardiac contraction may be reduced mainly due the loss of contractile proteins. The heart is therefore considered decompensated, which may result in heart failure. Both, adaptive and maladaptive hypertrophies are characterized by increased heart size and weight. RV: right ventricle and LV: left ventricle.

Hypertensive patients may progress from adaptive to maladaptive hypertrophy, which is characterized by increased left ventricle chamber accompanied by thinning of a left ventricle and septum wall (**Figure 1**). The myocytes are still hypertrophied, but the length is increased [1–3, 9]. The mechanisms involved in the transitions from adaptive to maladaptive hypertrophy are poorly understood. Nonetheless, some studies point out to the excessive matrix extracellular degradation during maladaptive hypertrophy disrupting the cellular organization [2], which could contribute to myocytes lengthening and left ventricular chamber dilatation. It has been also accepted that cell death is associated with this alteration in myocytes [2, 10].

Pathogenic cellular and interstitial changes in hypertension-induced cardiac remodeling are orchestrated by several molecular mechanisms that may be transduced from mechanical force into myocardial growth. In this regard, renin-angiotensin system (RAS) is activated in hypertension and may be involved in cardiac hypertrophy and failure. Clinical and experimental studies have shown significant benefit conferred by pharmacological blockade of RAS [7, 11–13] arousing interest by mechanisms underlying the action of angiotensin II (Ang II).

3. Angiotensin II and cardiac remodeling

Ang II is the primary effector peptide of the RAS. The hypertrophic effects of this peptide on the heart are associated with its vasoconstrictor and hypertensive properties. However, it is currently known that independently of its blood pressure effects, Ang II is a powerful hypertrophic agent. *In vitro* studies show that Ang II activates different hypertrophic signaling pathways in cardiac myocytes [11]. In addition, the crucial components to initiate synthetic route to Ang II production are present in the heart. Thus, Ang II is also locally synthesized at the myocardium, acting as an autocrine factor [11]. Increased cardiac Ang II synthesis is mediated, *in vitro*, by cardiomyocyte under stretch conditions [14]. Similarly, the rise in cardiac Ang II was also observed in hypertrophied heart from animals after overload pressure as well as in patients from end-stage heart failure, which suggests the hypertrophy have resulted from local RAS activation [11, 15].

The Ang II hypertrophic effects are mediated by the activation of specific receptor AT1 that plays a crucial role in heart failure pathophysiology, but both AT1 and AT2 receptor are present in the cardiac tissue [16–19]. The AT1 receptor is 7-transmembrane domain coupled to Gq protein (GPCR). Ang II is able to perform the signaling transduction to adaptive and maladaptive remodeling pathway [2]. AT1 receptor stimulated by Ang II leads to the protein kinase C activation [17], which in turn activates the mitogen-activated protein kinase (MAPK). The intracellular signaling cascade generated from MAPK is constituted by a phosphorylation-based amplification network and results in hypertrophic signals to cardiac adaptive or maladaptive remodeling [2, 10]. Three MAPKs, such as p38 kinases, c-Jun-terminal kinases (JNK) and ERK 1/2 have been described as signaling pathways in cardiac myocytes or extracellular matrix changes along the heart failure progression [10].

In the compensatory response to overload pressure, ERK 1/2 activation has been related to adaptive changes and increased width of the myocytes [20]. Further, some studies have suggested that JNK could contribute to maladaptive remodeling due to its pivotal role in cell death [2, 10, 21]. The MAPK signaling from cardiomyocyte cytoplasm drives to nuclei where transcriptional factors such as factor nuclear kappa B (NF- κ B), activating protein-1 (AP-1) and Smad are intracellular proteins to transduce extracellular signals from transforming growth factor beta ligands to the nucleus where they activate downstream gene transcription, rising the transcription of key proteins and developing essential function to the cardiac remodeling progression [22–25].

The NF- κ B is an oxidative-sensitive transcriptional factor [26]. Likewise, multiple signal transduction pathways are activated in response to reactive oxygen species (ROS) [27]. In this regard, emergent evidences have shown that Ang II-mediated hypertrophic response may be dependent of increased ROS production, particularly during hypertension [25, 28–30].

Several studies have confirmed the key role of ROS in the genesis and progression of cardiac remodeling [28, 31, 32]. Low levels of ROS are important to many downstream regulators in a physiological condition such as ion channel, receptors, kinases, phosphatases and transcriptional factor. However, increased ROS production characterizes oxidative stress, disrupts redox signaling within the cells and the interstice, promoting activation of calcium/calmodulin-dependent protein kinase I (CaMKI), increased NF- κ B, AP-1 and other transcriptional factors signaling [33, 34]. Oxidative stress also elicits post-transductional pathways that result in activation of some proteins, e.g., matrix metalloproteinases (MMP) [35]. Consequently, oxidative stress has been associated with cardiac contraction dysfunction, increased collagen deposition and myocytes hypertrophy that contribute to cardiac dysfunction, myocyte hypertrophy and cell death [27, 35].

Considering the relevance of ROS to cardiac diseases, a substantial body of studies has investigated which enzyme could be more important to ROS synthesis. Along the progression of cardiac remodeling, a family of complex enzymes termed nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) seems to play a central position to ROS production [27, 29]. Increased expression and activity of NADPH oxidase have been persistently observed in both preclinical and clinical studies of heart failure [27, 36]. There are seven Nox family isoforms (Nox1-5 and DUOX1 and 2), and the main cardiac enzymes are Nox2 and Nox4 [37].

Nox4 contribute to myocyte hypertrophy and cardiac fibrosis induced by AngII [38]. However, the role of Nox4 to cardiac hypertrophy is not yet fully comprehended [39].

Amount evidences show Nox2 associated with detrimental effects in the heart [27, 39]. The low-level activity of Nox2 is continuously present in the presence of nanomolar ROS levels but may be increased at the Ang II, endothelin, transforming growth factor (TGF)- β , tumor necrosis factor (TNF)- α presence as well as due to mechanical force [27]. Interestingly, Ang II-induced cardiac hypertrophy and fibrosis were reduced in knockout mice for Nox2 when compared to the wild type [38]. Currently, the contribution of Nox2 to Ang II hypertrophic effects appears to involve ERK1/2, Akt and NF- κ B signaling [27, 41, 43]. In addition, increased Ang II-induced MMP activation and expression seem to be dependent of ROS [30, 42, 44] resulting in cardiac adaptive remodeling and fibrosis [43, 44]. **Figure 2** summarizes relationship between Ang II-induced cardiac remodeling and Nox2.

The important signaling in Ang II-induced fibrosis predominantly requires the differentiation from fibroblast into myofibroblast cells [3]. This phenotypic transformation from fibroblast is characterized by α -smooth muscle actin (α -SMA) expression and increased production of extracellular matrix, which is a key event in connective tissue remodeling involved in the heart failure progression [3, 45]. Rossi [9] has shown an intensive and progressive accumulation of collagen, accompanied by increased heart weight in hypertensive subjects. In addition, the study revealed an association among connective matrix, cardiac systolic and diastolic dysfunction in

Figure 2. Main pathways concerning Ang II-induced cardiac remodeling. Nox2 is activated by Ang II via AT₁ receptor, triggering ROS formation, which activates intracellular pathways related to the cardiac hypertrophy. Nox2: NADPH oxidase isoform 2; ROS: reactive oxygen species; Akt: serine/threonine-specific protein kinase; ERK1/2: extracellular.

hypertension suggesting that collagen deposition could contribute to decreased myocardial compliance and disrupted heart electrical properties [9]. Currently, it is well known the relevance of fibrosis not only to the structure of the cardiac hypertrophy but also to the heart dysfunction [46]. Collagen is the main component of the extracellular matrix in the myocardium, which is synthesized by fibroblasts. However, its deposition in the heart during hypertension also depends of its degradation [3]. Thus, a large body of studies has shown the contribution of the MMP, which is the main proteases to collagen degradation, strongly contributing to the cardiac remodeling after pressure overload or infarct [28, 47]. The imbalances between MMP and endogenous tissue inhibitor (TIMP) are key mechanisms to control the collagen formation and deposition [2, 3, 48]. Indeed, some transcriptional factors such as AP-1 and NF- κ B may modulate the MMP activity increasing its MMP expression and also TIMP expression [28, 47]. Posttranslational mechanisms such as oxidative stress, particularly peroxynitrite and hydrogen peroxide, may activate MMP and inhibit TIMP activity [35, 49, 50], suggesting a possible mechanism to ROS-induced fibrosis in hypertensive rats [51]. Thus, MMP activity is regulated at three levels: (i) transcriptional level, (ii) endogenous inhibitors and (iii) factor activators (ROS). Interestingly, Ang II may increase MMP activity involving redox-sensitive signaling in fibroblast, thus triggering NF- κ B and AP-1 transcriptional factor activation [52]. In fact, antioxidant therapy reverses Ang II-induced cardiac hypertrophy and MMP activity in left ventricle from hypertensive rats [30]. Taken together, Ang II promotes myocyte on the heart and matrix extracellular hypertrophy by similar mechanisms involving redox signaling, which not only activates the RNA expression of proteins in the myocytes or fibroblasts, but also rises the activity of enzymes already present in the heart, such as MMP.

Furthermore, it must be recognized that Ang II induces inflammation by triggering cardiac remodeling. The proinflammatory effects of Ang II have been described since 1970 by Finn Olsen [53]. Thenceforward, several studies have supported the contribution of the inflammatory processes associated with Ang II to cardiovascular disorders, including hypertension and

heart remodeling [23, 25, 54]. Since inflammation contributes to this important clinical condition, numerous evidences have reported the connection between Ang II and two pivotal mediators for heart remodeling, the cytokines transforming growth factor (TGF)- β [23] and the tumoral necrosis factor (TNF)- α [25].

4. Angiotensin II and TGF- β in cardiac remodeling

Increased expression of TGF- β was found in the myocardium during cardiac hypertrophy and heart failure [55]. Classically, TGF- β is a multifunctional cytokine recognized as a powerful profibrotic factor. Three isoforms of the TGF- β family have been identified in mammals [56], but TGF- β 1 has been constantly associated with several cardiovascular diseases, particularly during the transition from adaptive cardiac hypertrophy into heart failure [56–59]. The overexpression of TGF- β 1 induced fibrosis and myocyte hypertrophy in transgenic mice after they were 8 weeks old [58]. Upregulated TGF- β 1 mRNA is found in the pressure-overloaded human heart [60], as well as in the dilated cardiomyopathy [57]. The latent form of TGF- β 1 is composed of 390-amino acid complexed with the signal peptide and the large amino-terminal prodomains (known as latency-associated proteins, LAPs) which are required for correct folding and dimerization of the carboxyl terminal domain of the growth factor (the mature peptide) [61]. TGF- β 1 can be released and activated by the proteolytic cleavage, which disrupts its non-covalent attachment with LAP [62]. The intracellular signaling induced by TGF- β underlies the activation of serine/threonine kinases receptor resulting in Smad phosphorylation, which is responsible to activate target genes [61]. TGF- β may also promote the regulation of the transcription by TGF- β -activated kinase-1 (TAK1) triggering p38 MAPK phosphorylation and activating transcriptional factor (ATF)-2 [56].

Myriad experimental studies reported Ang II-mediated TGF-beta induction, particularly of its expression [63–65]. AT1 receptor seems to be involved with TGF- β upregulation expression at the transcriptional level in as much as losartan treatment inhibited the rise of this cytokine in animals after Ang II infusion [63].

Since AT1 activation produces ROS via NADPH oxidase, Wenzel et al. [63] demonstrated that the induction of TGF- β in cardiomyocytes was diminished in the presence of NADPH oxidase inhibitors. Consistently, antioxidant treatments have shown decreased cardiac TGF- β expression in the experimental model of RAS activation [23, 30]. The redox signaling involved in Ang II-induced TGF- β upregulation seems to be dependent on p38 MAPK and AP-1 pathway, such was observed in ventricular cardiac myocytes [23, 63]. In this regard, the first direct evidence about the causal relation between two important factors for cardiac hypertrophy (Ang II e TGF- β) was observed in TGF- β 1-deficient mice. The marked cardiac hypertrophy and the impaired cardiac function induced by chronic suppressor doses of Ang II were not observed in TGF- β 1-deficient mice [66]. Thus, cardiac TGF- β is required to hypertrophy signaling induced by Ang II, which in turn activates its AT1 receptor upregulating this cytokine expression.

TGF- β and Ang II are involved in fibroblast differentiation and MMP activity control [3]. In this regard, an imbalance between MMP/TIMP is possibly another common signaling consequently

involved in the heart hypertrophy. Ang II-induced increased MMP transcriptional expression has been reported by several studies [30, 42, 44]. Despite AP-1 contribution to the transcription of MMP-2 [47], the NF- κ B inhibition attenuated MMP-2 upregulation in both heart and aorta from 2-kidney and 1-clip (2K1C) hypertensive rats [44]. Transgenic mice overexpressing cardiac MMP-2 presented marked decompensated hypertrophy, including not only collagen deposition but also significant systolic dysfunction [67]. MMP-2 seems to degrade some contractile proteins from heart sarcomeres, such as myosin and troponin [35], which have constantly been associated with impaired heart capacity to contract in experimental models of heart disease [68]. In this regard, several findings have stated that MMP-2 inhibition ameliorates remodeling and cardiac dysfunction [35, 47, 69]. In addition, Ang II-induced MMP activation may be associated with adaptive remodeling and cardiac dysfunction in 2K1C rats [69]. The Ang II activates MMP-2 by mechanisms involving NADPH oxidase activation and ROS formation [30, 42]. In this sense, TGF- β could increase MMP-2 activation since this cytokine also increases ROS formation. Indeed, some studies have shown increased TGF- β levels and MMP-2 activity in the left ventricle from hypertensive rats [3, 30]. Hence, the TGF- β -dependent mechanisms to Ang II-induced cardiac remodeling may involve MMP-2 activation by redox signaling. However, future studies are necessary to support the causal relation between MMP-2 activation and TGF- β in Ang II hypertrophy.

5. Angiotensin II and TNF- α in cardiac remodeling

The proinflammatory cytokine TNF- α was first defined as an antimitogenic. Nowadays, amount findings revealed a wide range of pleiotropic TNF- α effects including cell proliferation, apoptosis and production of other proinflammatory cytokines [2].

Growing body of evidences evaluated the role of TNF- α in many diseases, particularly in cardiovascular disease. TNF- α has been found upregulated in myocardial from humans and animals with heart failure [70]. A wide variety of cells including macrophages, fibroblast and endothelial cells produce TNF- α . It has been described that cardiomyocytes themselves are capable of synthesizing TNF- α [71]. Bryant et al. [72] have shown that TNF- α synthesized by cardiomyocytes was sufficient to cause severe cardiac remodeling suggesting maladaptive hypertrophy, which may also occur in human heart failure.

The TNF- α is secreted as a cell surface protein (homotrimeric type II transmembrane protein) containing 233-amino-acid, which is activated by proteolytic cleavage to a 76-amino-acid signal peptide [73, 74]. The TNF- α released as a mature protein, which acts as a soluble cytokine through its two receptors: TNF receptor 1 (TNFR1) and TNFR2 [75, 76]. Despite the homology between TNFR1 and TNFR2 in extracellular domains, both intracellular domains of TNFR1 and TNFR2 are different. Once activated, TNFR1 leads to recruitment of a protein TRADD (TNFR1 associated death domain protein), which subsequently interacts with three other intracellular proteins forming a complex. When activated, TNFR2 directly recruits TRAF2 and TRAF1 (TNF receptor-associated factor). These differences in TNFR-induced intracellular signaling suggest each receptor has distinct cellular functions. In this sense, dual effects of TNF- α have been

suggested during the progress of cardiac disease. Low concentration of TNF- α has been associated with the protective effects while its high concentrations present deleterious effects [77]. This study did not evaluate the TNF- α receptors contribution. However, other evidences have been shown that the effects of the two receptors on heart failure were opposite, TNFR1 showed proapoptotic and prohypertrophic while TNFR2 developed antiapoptotic and antihypertrophic effects [78]. In addition, other findings have suggested that TNFR1 is responsible for the major deleterious effects produced by TNF- α in hypertrophic signaling [79, 80]. Moreover, soluble TNFR1 is a predictor of mortality and heart failure in patients with acute myocardial infarct [81]. Preclinical studies demonstrated that TNFR1 plays an important role in Ang II-induced fibrosis in rats while TNFR2 did not affect the increased collagen deposition in response to Ang II infusion [80].

TNF- α -induced intracellular signaling involves canonical NF- κ B activation. The complex of intracellular protein is formed when TNFR1 is activated, specific mitogen-activated protein kinase kinases (MAPKKs) are phosphorylated consequently activating c-Jun N terminal kinase (JNK), AP1 and p38 MAPK signaling pathways. Taken together, TNF- α -induced intracellular signaling controls the expression of inflammatory proteins and antiapoptotic genes. Another signaling complex is triggered as a response to the TNFR1 activation resulting in stimulation of the effective caspases, which in turn lead to apoptosis [82].

TNF- α has induced increased ROS formation in endothelial cells by a mechanism dependent of NADPH oxidase subunit: p47 phox subunit [83]. Indeed, cardiomyocytes hypertrophy was induced by recombinant human TNF- α at least in part due to ROS generation [84]. Through experimental models of heart failure, TNF- α inhibition decreased oxidative stress and apoptosis improving cardiac remodeling and dysfunction [85]. Thus, ROS seems to foster a key function in the cardiac hypertrophy induced by TNF- α .

As described above, it is possible to observe common signaling pathways between TNF- α and Ang II. Since Ang II notably has increased TNF- α *in vivo* [86] and *in vitro* studies [87], some evidences have reported a potential role of TNF- α in Ang II-induced cardiac hypertrophy [25, 88–90]. In this context, chronic Ang II infusion promotes cardiac hypertrophy, which was attenuated in TNF- α knockout mice [89]. These findings were further confirmed by the pharmacological inhibition by etanercept, an inhibitor of TNF- α , which blunted cardiac hypertrophy in mice under Ang II infusion [25]. Indeed, the authors showed the involvement of TNF- α in the intracellular signaling in Ang II-induced hypertrophy. Both TNF- α and Ang II induced activation of NF- κ B, p38 MAPK and JNK. Accordingly, heart TNF- α knockout mice attenuated the activation of NF- κ B, p38 MAPK and JNK signaling in Ang II infusion, suggesting TNF- α is required to induce Ang II cardiac hypertrophy by intracellular signaling pathways [25]. It was observed that the TNFR1 deficient mice did not develop fibrosis under Ang II stimulation, while TNFR2 deficient mice showed increased collagen accumulation in the heart under Ang II infusion [88], which may indicate a promising role of TNF- α in activating TNFR1 as crucial signaling to Ang II inducing cardiac remodeling.

Ang II and TNF- α are involved in increased production of ROS, which in turn activate NF- κ B. In this regard, Sriramula et al. [25] also suggest that redox signaling induced by Ang II may be dependent of TNF- α . The authors have found that the increased mRNA, 2 expression and

also the expression of other NADPH oxidase isoforms were blunted in TNF- α knockout mice, which have resulted in lower levels of ROS. Collectively, all findings point out to a causal relation between hypertrophic signaling of Ang II and TNF- α that involve redox pathways on NF- κ B, JNK and p38 activation.

6. Conclusion

Ang II and these cytokines (TGF- β and TNF- α) activate some intracellular pathways involved in hypertrophy, including increased ROS production through NADPH oxidase. Ang II activates NF- κ B, which is a possible mechanism to Ang II-induced increased levels TNF- α and other proinflammatory cytokines. NF- κ B and ROS pathway seems to be also involved TGF- β -increased MMP activity. In addition, cytokines, TNF- α and TGF- β , and Ang II are closely related with a MAPK, which is a known key pathway involved in cardiac hypertrophy and MMP regulation. Taken together, Ang II is associated to the TNF- α and TGF- β by mechanisms involving ROS-NF- κ B-MMP then contributing to the heart failure.

Author details

Carolina Baraldi Araujo Restini^{1,2*}, Arthur F. Engracia Garcia¹, Henrique Melo Natalin¹, Guilherme Melo Natalin¹ and Elen Rizzi²

*Address all correspondence to: carolbaraldi@hotmail.com

1 Medical School, University of Ribeirao Preto, SP-UNAERP, São Paulo, Brazil

2 Department of Biotechnology, University of Ribeirao Preto, SP-UNAERP, São Paulo, Brazil

References

- [1] Rossi MA, Carillo SV. Cardiac hypertrophy due to pressure and volume overload: distinctly different biological phenomena? *Int J Cardiol* 1991;31:133–41. DOI: 10.1016/0167-5273(91)90207-6.
- [2] Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodeling. *Lancet* 2006;367:356–67. DOI: 10.1016/S0140-6736(06)68074-4.
- [3] Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. *J Clin Invest* 2007;117:568–75. DOI: 10.1172/JCI31044.
- [4] Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/

- American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol* 2005;46:e1-82. DOI: 10.1016/j.jacc.2005.08.022.
- [5] Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013;6:606–19 DOI: 10.1161/HHF.0b013e318291329a.
- [6] Roger VL. Epidemiology of heart failure. *Circ Res* 2013;113:646–59 DOI: 10.1161/CIRCRESAHA.113.300268.
- [7] Dusing R. Mega clinical trials which have shaped the RAS intervention clinical practice. *Ther Adv Cardiovasc Dis* 2016;10:133–501. DOI: 10.1177/1753944716644131.
- [8] Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. *JAMA* 1996;275:1557–62. DOI: 10.1001/jama.1996.03530440037034
- [9] Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. *J Hypertens* 1998;16:1031–41. PMID:9794745
- [10] Opie LH. Cellular basis for therapeutic choices in heart failure. *Circulation* 2004;110:2559–61. DOI: 10.1161/01.CIR.0000146803.14063.F7.
- [11] Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. *Cardiovasc Res* 1999;43:838–49. DOI: 10.1016/S0008-6363(99)00145-5.
- [12] Tamargo J, Lopez-Sendon J. Novel therapeutic targets for the treatment of heart failure. *Nat Rev Drug Discov* 2011;10:536–55. DOI:10.1038/nrd3431.
- [13] Martins-Oliveira A, Castro MM, Oliveira DM, Rizzi E, Ceron CS, Guimaraes D, et al. Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling. *Int J Cardiol* 2013;167:1199–20. DOI: 10.1016/j.ijcard.2012.03.137.
- [14] Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. *J Clin Invest* 1998;101:1326–42. DOI: 10.1172/JCI316.
- [15] De Mello WC, Danser AH. Angiotensin II and the heart: on the intracrine renin-angiotensin system. *Hypertension* 2000;35:1183-8. DOI: 10.1161/01.HYP.35.6.1183.
- [16] Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M. Characterization of angiotensin II receptor subtypes in rat heart. *Circ Res* 1992;71:1482-9. DOI: 10.1161/01.RES.71.6.1482

- [17] Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers. *Circ Res* 1993;73:424–38. DOI: 10.1161/01.RES.73.3.424
- [18] Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. *Circ Res* 1993;73:439–47. DOI:10.1161/01.RES.73.3.439
- [19] Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, et al. Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. *Am J Physiol* 1994;267:H844–52. PMID:8067441
- [20] Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. *EMBO J* 2000;19:6341–50 DOI: 10.1093/emboj/19.23.6341.
- [21] Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. *Physiol Rev* 2010;90:1507–46. DOI: 10.1152/physrev.00054.2009 [doi].
- [22] Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. *Mol Cell Biochem* 2000;212:155–69. PMID:11108147
- [23] Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. *Cardiovasc Res* 2004;63:423–32. DOI: 10.1016/j.cardiores.2004.04.030.
- [24] Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. *Cell Mol Life Sci* 2006;63:2584–96. DOI:10.1007/s00018-006-6085-8.
- [25] Sriramula S, Francis J. Tumor necrosis factor-alpha is essential for angiotensin II-induced ventricular remodeling: role for oxidative stress. *PLoS One* 2015;10:e0138372. DOI:10.1371/journal.pone.0138372.
- [26] Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. *Cardiovasc Res* 2006;71:226–35. DOI:10.1016/j.cardiores.2006.04.015.
- [27] Sag CM, Santos CX, Shah AM. Redox regulation of cardiac hypertrophy. *J Mol Cell Cardiol* 2014;73:103–11. DOI:10.1016/j.yjmcc.2014.02.002.
- [28] Deschamps AM, Spinale FG. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. *Cardiovasc Res* 2006;69:666–76. DOI:10.1016/j.cardiores.2005.10.004.
- [29] Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. *Curr Hypertens Rep* 2010;12:135–42. DOI:10.1007/s11906-010-0100-z.
- [30] Rizzi E, Castro MM, Ceron CS, Neto-Neves EM, Prado CM, Rossi MA, et al. Tempol inhibits TGF-beta and MMPs upregulation and prevents cardiac hypertensive changes. *Int J Cardiol* 2013;165:165–73. DOI: 10.1016/j.ijcard.2011.08.060.

- [31] Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. *Cardiovasc Res* 2006;71:208–15. DOI: 10.1016/j.cardiores.2006.03.016.
- [32] Zhang M, Perino A, Ghigo A, Hirsch E, Shah AM. NADPH oxidases in heart failure: poachers or gamekeepers? *Antioxid Redox Signal* 2013;18:1024–41. DOI: 10.1089/ars.2012.4550.
- [33] Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. *Heart Fail Rev* 2004;9:43–51. DOI: 10.1023/B:HREV.0000011393.40674.13.
- [34] Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology and pathology. *Circ Res* 2012;111:1091–106. DOI: 10.1161/CIRCRESAHA.111.255216.
- [35] Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. *Annu Rev Pharmacol Toxicol* 2007;47:211–42. DOI:10.1146/annurev.pharmtox.47.120505.105230.
- [36] Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, et al. Increased myocardial NADPH oxidase activity in human heart failure. *J Am Coll Cardiol* 2003;41:2164–71. DOI: :10.1016/S0735-1097(03)00471-6.
- [37] Lassegue B, San Martin A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. *Circ Res* 2012;110:1364–90. DOI: 10.1161/CIRCRESAHA.111.243972.
- [38] Zhao QD, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X, et al. NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFkappaB signaling pathways. *Circulation* 2015;131:643–55. DOI: 10.1161/CIRCULATIONAHA.114.011079.
- [39] Shah AM. Parsing the role of NADPH oxidase enzymes and reactive oxygen species in heart failure. *Circulation* 2015;131:602-4. DOI: 10.1161/CIRCULATIONAHA.115.014906.
- [40] Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. *Circulation* 2002;105:293-6. DOI: 10.1161/hc0302.103712.
- [41] Sarman B, Skoumal R, Leskinen H, Rysa J, Ilves M, Soini Y, et al. Nuclear factor-kappaB signaling contributes to severe, but not moderate, angiotensin II-induced left ventricular remodeling. *J Hypertens* 2007;25:1927–39. DOI: 10.1097/HJH.0b013e3281e66653.
- [42] Luchtefeld M, Grote K, Grothusen C, Bley S, Bandlow N, Selle T, et al. Angiotensin II induces MMP-2 in a p47phox-dependent manner. *Biochem Biophys Res Commun* 2005;328:183-8. DOI: 10.1016/j.bbrc.2004.12.152.

- [43] Belo VA, Guimaraes DA, Castro MM. Matrix metalloproteinase 2 as a potential mediator of vascular smooth muscle cell migration and chronic vascular remodeling in hypertension. *J Vasc Res* 2015;52:221–31. DOI: 10.1159/000441621.
- [44] Cau SB, Guimaraes DA, Rizzi E, Ceron CS, Gerlach RF, Tanus-Santos JE. The nuclear factor kappaB inhibitor pyrrolidine dithiocarbamate prevents cardiac remodelling and matrix metalloproteinase-2 up-regulation in renovascular hypertension. *Basic Clin Pharmacol Toxicol* 2015;117:234–41. DOI: 10.1111/bcpt.12400.
- [45] Gonzalez A, Lopez B, Querejeta R, Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? *J Mol Cell Cardiol* 2002;34:1585–93. DOI: 10.1006/jmcc.2002.2081.
- [46] Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. *J Mol Cell Cardiol* 1994;26:279–92. DOI: 10.1006/jmcc.1994.1036.
- [47] Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. *Physiol Rev* 2007;87:1285–342. DOI: 10.1152/physrev.00012.2007.
- [48] Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. *Biochim Biophys Acta* 2010;1803:55–71. DOI: 10.1016/j.bbamcr.2010.01.003.
- [49] Donnini S, Monti M, Roncone R, Morbidelli L, Rocchigiani M, Oliviero S, et al. Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4. *FEBS Lett* 2008;582:1135–40. DOI: 10.1016/j.febslet.2008.02.080.
- [50] Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. *Cardiovasc Res* 2010;85:413–23. DOI: 10.1093/cvr/cvp268 [doi].
- [51] Rizzi E, Ceron CS, Guimaraes DA, Prado CM, Rossi MA, Gerlach RF, et al. Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-beta in renovascular hypertension-induced cardiac hypertrophy. *Exp Mol Pathol* 2013;94:1–9. DOI: 10.1016/j.yexmp.2012.10.010.
- [52] Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. *Am J Physiol Heart Circ Physiol* 2006;291:H1738–45. DOI: 10.1152/ajpheart.00341.2006.
- [53] Olsen F. Type and course of the inflammatory cellular reaction in acute angiotensin-hypertensive vascular disease in rats. *Acta Pathol Microbiol Scand A* 1970;78:143–50. DOI: 10.1111/j.1699-0463.1970.tb00249.x.
- [54] McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. *Circ Res* 2015;116:1022–33. DOI: 10.1161/CIRCRESA-HA.116.303697.

- [55] Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. *Cardiovasc Res* 2007;74:184–95. DOI: 10.1016/j.cardiores.2006.10.002.
- [56] Poniatowski LA, Wojdasiewicz P, Gasik R, Szukiewicz D. Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications. *Mediators Inflamm* 2015;2015:137823–40 DOI: 10.1155/2015/137823.
- [57] Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. *Circulation* 1999;99:2750–6. DOI: 10.1161/01.CIR.99.21.2750.
- [58] Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). *Am J Physiol Heart Circ Physiol* 2002;283:H1253–62. DOI 10.1152/ajpheart.00578.2001.
- [59] Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. *Cardiovasc Res* 2011;89:265–72. DOI: 10.1093/cvr/cvq308.
- [60] Villar AV, Llano M, Cobo M, Exposito V, Merino R, Martin-Duran R, et al. Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. *J Mol Cell Cardiol* 2009;46:526–35 DOI:10.1016/j.yjmcc.2008.12.024.
- [61] Massague J, Seoane J, Wotton D. Smad transcription factors. *Genes Dev* 2005;19:2783–810. DOI: 10.1101/gad.1350705.
- [62] Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. *J Cell Biol* 1988;106:1659–65.PMCID: PMC2115066.
- [63] Wenzel S, Taimor G, Piper HM, Schluter KD. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. *FASEB J* 2001;15:2291–310. DOI: 1096/fj.00-0827fj.
- [64] Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. *Hypertension* 2000;35:1078–84. DOI: 10.1161/01.HYP.35.5.1078.
- [65] Wheeler JB, Ikonomidis JS, Jones JA. Connective tissue disorders and cardiovascular complications: the indomitable role of transforming growth factor-beta signaling. *Adv Exp Med Biol* 2014;802:107–27. DOI: 10.1007/978-94-007-7893-1_8.
- [66] Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. *J Clin Invest* 2002;109:787–96. DOI: 10.1172/JCI14190.

- [67] Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. *Am J Physiol Heart Circ Physiol* 2007;292:H1847–60. DOI: 10.1152/ajpheart.00434.2006.
- [68] Hughes BG, Schulz R. Targeting MMP-2 to treat ischemic heart injury. *Basic Res Cardiol* 2014;109:424. DOI: 10.1007/s00395-014-0424-y.
- [69] Rizzi E, Castro MM, Prado CM, Silva CA, Fazan R, Jr., Rossi MA, et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. *J Card Fail* 2010;16:599–608. DOI: 10.1016/j.cardfail.2010.02.005.
- [70] Torre-Amione G, Vooletich MT, Farmer JA. Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. *Drugs* 2000;59:745–51. DOI: 10.2165/00003495-200059040-00002.
- [71] Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. *Circ Res* 1997;81:187–95. DOI: 10.1161/01.RES.81.2.187.
- [72] Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. *Circulation* 1998;97:1375–81. DOI: 10.1161/01.CIRC.97.14.1375.
- [73] Camussi G, Albano E, Tetta C, Bussolino F. The molecular action of tumor necrosis factor-alpha. *Eur J Biochem* 1991;202:3-14. DOI: 10.1111/j.1432-1033.1991.tb16337.x.
- [74] Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. *FEBS Lett* 1998;435:39–44. DOI: 10.1016/S0014-5793(98)01031-X.
- [75] Tartaglia LA, Goeddel DV. Two TNF receptors. *Immunol Today* 1992;13:151–301. DOI: 10.1016/0167-5699(92)90116-O.
- [76] Winsauer C, Kruglov AA, Chashchina AA, Drutskaya MS, Nedospasov SA. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. *Cytokine Growth Factor Rev* 2014;25:115–23. DOI: 10.1016/j.cytogfr.2013.12.005 [doi].
- [77] Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. *Annu Rev Physiol* 2003;65:81–101. DOI: 10.1146/annurev.physiol.65.092101.142249.
- [78] Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. *Circulation* 2009;119:1386–97. DOI: 10.1161/CIRCULATIONAHA.108.802918.

- [79] von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor- α and the failing heart--pathophysiology and therapeutic implications. *Basic Res Cardiol* 2004;99:18–28. DOI: 10.1007/s00395-003-0433-8.
- [80] Duerrschmid C, Crawford JR, Reineke E, Taffet GE, Trial J, Entman ML, et al. TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. *J Mol Cell Cardiol* 2013;57:59–67. DOI: 10.1016/j.yjmcc.2013.01.006.
- [81] Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor necrosis factor- α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. *Circulation* 2005;111:863–70. DOI: 10.1161/01.CIR.0000155614.35441.69.
- [82] Borghi A, Verstrepen L, Beyaert R. TRAF2 multitasking in TNF receptor-induced signaling to NF- κ B, MAP kinases and cell death. *Biochem Pharmacol* 2012; 116 (15): 1–10. DOI:10.1016/j.bcp.2016.03.009.
- [83] Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ, et al. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor- α . *Circ Res* 2002;90:143–50. DOI: 10.1161/hh0202.103615.
- [84] Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor- α and angiotensin II. *Circulation* 1998;98:794–9. DOI: 10.1161/01.CIRC.98.8.794.
- [85] Moe GW, Marin-Garcia J, Konig A, Goldenthal M, Lu X, Feng Q. In vivo TNF- α inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. *Am J Physiol Heart Circ Physiol* 2004;287:H1813–20. DOI: 10.1152/ajpheart.00036.2004.
- [86] Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial J, et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. *J Mol Cell Cardiol* 2010;49:499–507. DOI: 10.1016/j.yjmcc.2010.05.005.
- [87] Pellieux C, Montessuit C, Papageorgiou I, Lerch R. Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor- α . *Cardiovasc Res* 2009;82:341–50. DOI:10.1093/cvr/cvp004 [doi].
- [88] Duerrschmid C, Trial J, Wang Y, Entman ML, Haudek SB. Tumor necrosis factor: a mechanistic link between angiotensin-II-induced cardiac inflammation and fibrosis. *Circ Heart Fail* 2015;8:352–61. DOI: 10.1161/CIRCHEARTFAILURE.114.001893.
- [89] Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factor- α in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hyper-

trophy. *Hypertension* 2008;51:1345–51. DOI: 10.1161/HYPERTENSIONAHA . 107.102152.

- [90] Sriramula S, Cardinale JP, Francis J. Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension. *PLoS One* 2013;8:e63847–56. DOI: 10.1371/journal.pone.0063847.

IntechOpen

IntechOpen